Icon

VOTRIENT (nda022465)- (EQ 200MG BASE,EQ 400MG BASE)

PAZOPANIB HYDROCHLORIDE NOVARTIS
EQ 200MG BASE,EQ 400MG BASE
No No
2023-Oct-19 2014-Oct-19
2019-Apr-26 None
None No
VOTRIENT is a kinase inhibitor indicated for the treatment of patients with: • advanced renal cell carcinoma. • advanced soft tissue sarcoma who have received prior chemotherapy.
5 0 5
Total Other Developers 18
Drugs with Suitability No
EQ 200MG BASE ** ** - - -
EQ 400MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 3
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** **** ****** *** ***** ******** *.*.*. *********** ****** ****** ********** **, ******, *****, ******* (***) ***
****** ****** ****** ***. *********** *** ****** *****, *******, ******* *** ***, ****** (***) ***
****** ******* ***** **** ******* ******* *********** **** **. *-*/*, ****** ********** ****** ****** ********, *********** ********, ***** **** ******, ***** (***) ***
****** ******* ******* ******** ***. ***. *********** ** ** ***** ******* ********* *, ***** ********* ****** **** *, ********@******, ****** ******, ****** ******** *****, ******** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-*, **. **. ***, *** & ***, ******* *******, ********* ******, *******-**********, ********* ******, ***** (***) ***

GenUs Advanced Search




Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.